Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17306126 | 0.87 | SLC18A3 (0.49) | DRD2SLC18A3TLR9TLR8TLR7 | |
| SCHEMBL23374690 | 0.85 | SLC18A3 (0.49) | DRD2SLC18A3TLR9TLR8TLR7 | |
| SCHEMBL14923996 | 0.85 | DRD2 (0.54) | DRD2SLC18A3TLR9TLR8TLR7 | |
| SCHEMBL6247690 | 0.83 | SLC18A3 (0.57) | DRD2SLC18A3TLR9TLR8TLR7 | |
| SCHEMBL1099798 | 0.83 | SLC18A3 (0.67) | DRD2SLC18A3GRM2 | |
| SCHEMBL20004333 | 0.81 | DRD2 (0.54) | DRD2SLC18A3HPGDPRCP | |
| SCHEMBL9347958 | 0.81 | SLC18A3 (0.46) | DRD2SLC18A3TLR9TLR8TLR7 | |
| SCHEMBL23692934 | 0.81 | SLC18A3 (0.64) | DRD2SLC18A3TLR9TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL9343733 | 0.80 | SLC18A3 (0.44) | DRD2SLC18A3TLR9TLR8TLR7 | |
| SCHEMBL20883775 | 0.80 | TLR9 (0.48) | DRD2SLC18A3TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | HDAC6, HDAC9, HDAC7 | DRD2 354/4885SLC18A3 3128/4885TLR9 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.